SickKids, officially known as The Hospital for Sick Children, is a premier institution dedicated to advancing pediatric health through cutting-edge research and innovation. Located in the Peter Gilgan Centre for Research and Learning, the largest child health research tower globally, SickKids operates within the healthcare and biotechnology sectors. The institution primarily serves pediatric patients and their families, but its research and innovations have broader health, social, and economic impacts.

The SickKids Industry Partnerships and Commercialization (IP&C) office plays a pivotal role in identifying, developing, and commercializing health research, technology, and innovations created by its scientists and clinicians. By partnering with industry leaders and investors, SickKids translates groundbreaking research into market-ready products. This collaboration not only accelerates the commercialization process but also ensures that innovations reach those who need them most, thereby generating significant licensing revenue.

SickKids' business model revolves around leveraging its robust innovation ecosystem to foster research collaborations and commercial partnerships. The institution generates revenue through licensing agreements, research grants, and partnerships with pharmaceutical companies, biotech firms, and other healthcare organizations. By demystifying the commercialization process, SickKids helps innovators transform their intellectual property into viable products, contributing to the institution's financial sustainability and its mission to improve pediatric health outcomes.

Keywords: pediatric health, innovation, commercialization, research, licensing revenue, biotechnology, healthcare, partnerships, intellectual property, SickKids.